Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02268214
Recruitment Status : Completed
First Posted : October 20, 2014
Results First Posted : March 29, 2018
Last Update Posted : September 13, 2018
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: Dapagliflozin Drug: Placebo for dapagliflozin Phase 3

Detailed Description:
Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 833 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus
Actual Study Start Date : November 11, 2014
Actual Primary Completion Date : January 4, 2017
Actual Study Completion Date : August 25, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Arm A: Dapagliflozin
Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Tablets

Experimental: Arm B: Dapagliflozin
Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Tablets

Placebo Comparator: Arm C: Placebo for Dapagliflozin
Placebo tablet orally, once daily for 52 weeks
Drug: Placebo for dapagliflozin
Tablets




Primary Outcome Measures :
  1. Adjusted Mean Change in HbA1c From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model[RMM]).


Secondary Outcome Measures :
  1. Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model[RMM])

  2. Adjusted Mean Percent Change in Body Weight From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model[RMM])

  3. Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model[RMM])

  4. Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model[RMM])

  5. Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model[RMM])

  6. Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events [ Time Frame: From Baseline to Week 24 ]
    Subjects with HbA1c reduction from baseline to week 24 (LOCF) >= 0.5% and without severe hypoglycemia events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Type 1 Diabetes mellitus (T1DM)
  • Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)
  • Insulin use for at least 12 months per patient reported or medical records
  • Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening
  • Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening
  • If on MDI insulin administration, subject must be on ≥ 3x injections per day
  • Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%
  • Body mass index (BMI) ≥ 18.5 kg/m2

Exclusion Criteria:

  • History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity
  • Taking metformin and/or thiazolidinediones within 2 months prior to screening
  • Taking any antidiabetic medication (other than insulin), within 1 month prior to screening

    - Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration

  • History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening
  • History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening
  • Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening
  • History of Addison's disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02268214


  Show 131 Study Locations
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Anna Maria Langkilde AstraZeneca

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02268214     History of Changes
Other Study ID Numbers: MB102-229
2013-004674-97 ( EudraCT Number )
D1695C00006 ( Other Identifier: AstraZenenca )
First Posted: October 20, 2014    Key Record Dates
Results First Posted: March 29, 2018
Last Update Posted: September 13, 2018
Last Verified: August 2018
Keywords provided by AstraZeneca:
Dapagliflozin
Efficacy
Safety
Add on to insulin
Oral Antidiabetic
Type 1 diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action